top of page
Get in touch
Menu
Close
About us
The science
The team
The opportunity
The news
Let's transform lives together
First name
*
Last name
*
Your Email
*
Write your short message here
Yes, please add me to your contacts
*
Submit
Our latest news
Drug Target Review features an insightful article by Dan Williams that explores the extraordinary achievements of AI in drug design
Dec 4, 2025
Technology Networks features a major interview with Dr Uwe Meya, SynaptixBio’s CMO, in which the issues around organising, funding, and conducting clinical trials for rare diseases are discussed.
Nov 27, 2025
Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis
Nov 4, 2025
Dan Williams welcomes news that NICE has raised the cost-effectiveness threshold for ultra-rare disease drugs
Oct 8, 2025
Part 3 of Dan Williams’ interview for BioPharm International
Oct 8, 2025
Part 2 of Dan Williams’ interview for BioPharm International
Sep 9, 2025
Dan Williams interviewed for prestigious BioPharm International podcast - Part 1
Aug 31, 2025
Dan Williams interviewed on NBC about the impacts of proposed cuts on rare disease research
Jul 21, 2025
SynaptixBio reaches hugely significant milestone with selection of candidate drug for clinical trials
Jul 8, 2025
Dan Williams welcomes new government newborn screening initiative but calls for plan details
Jul 8, 2025
Dan Williams discusses gene silencing in this important piece for Drug Target Review
Apr 15, 2025
SynaptixBio’s fourth anniversary celebrated in The Lifesciences Magazine
Apr 15, 2025
In a major article for Drug Discovery World, Dan Williams discussed the opportunities for ASO-based therapies
Apr 15, 2025
Dan Williams makes the business case for rare disease drugs in a major piece for The Journal of mHealth
Mar 22, 2025
SynaptixBio contributes to PharmaSources analysis of antisense technology
Mar 22, 2025
Dan Williams interviewed for BBC story about Bethany, who is living with H-ABC
Mar 22, 2025
In a major article for Pharmaceutical Market Europe, SynaptixBio explains the science behind gene silencing technology
Jan 30, 2025
Dan Williams discusses SynaptixBio’s history, status, and aspirations in a major interview for leading US biotech podcast RAREcast
Jan 9, 2025
The market for ‘gene silencing’ therapies is set to explode
Dec 16, 2024
Amy Sheridan-Hill, co-founder of the H-ABC Foundation, and Dan Williams in major Mirror story about hopes for new drug
Oct 31, 2024
About us
The science
The team
The opportunity
The news
bottom of page
